Key terms
About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest REGN news
Yesterday
1:15am ET
Buy Rating Affirmed for Regeneron on Strong Product Sales and Promising Pipeline
May 03
8:23am ET
Analysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)
May 03
8:08am ET
Regeneron (REGN) Receives a Buy from Oppenheimer
May 03
7:30am ET
Truist Financial Keeps Their Buy Rating on Regeneron (REGN)
May 03
6:47am ET
Buy Rating Affirmed for Regeneron on Strong Product Performance and Promising Pipeline Developments
May 03
6:36am ET
Buy Rating Affirmed: Regeneron’s Promising Pipeline and Potential for Surpassing Earnings Expectations
May 02
9:06am ET
Regeneron says FDA requested additional analyses during Dupixent sBLA review
May 02
9:03am ET
Regeneron 10-Q cites FDA calling for more Dupi data, says RBC Capital
May 02
6:34am ET
Regeneron lowers FY24 CapEx view to $780M-$880M from $825M-$950M
May 02
6:32am ET
Regeneron announces new $3B share repurchase program
May 02
6:31am ET
Regeneron reports Q1 adjusted EPS $9.55, consensus $10.10
May 01
8:25pm ET
Notable companies reporting before tomorrow’s open
May 01
1:55pm ET
Notable companies reporting before tomorrow’s open
May 01
7:33am ET
Regeneron sees FY24 adjusted EPS $1.42-$1.49, consensus $1.46
Apr 30
7:20am ET
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), DocGo (DCGO) and Revvity (RVTY)
Apr 29
7:16am ET
Regeneron announces presentations on EYLEA HD, EYLEA Injection at ARVO meeting
Apr 26
8:41am ET
Regeneron price target raised to $1,175 from $1,125 at Oppenheimer
Apr 26
8:21am ET
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)
Apr 26
4:48am ET
Barclays Sticks to Their Buy Rating for Regeneron (REGN)
Apr 25
7:28am ET
Regeneron, Mammoth collaborate to purse next-generation gene editing
Apr 25
5:44am ET
Wells Fargo Reaffirms Their Buy Rating on Regeneron (REGN)
Apr 22
8:29am ET
Regeneron (REGN) Gets a Buy from Piper Sandler
Apr 17
9:00am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 17
6:55am ET
Cantor Fitzgerald Reaffirms Their Hold Rating on Regeneron (REGN)
Apr 12
8:33am ET
Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Regeneron (REGN)
Apr 12
7:00am ET
Regeneron price target raised to $720 from $710 at BofA
Apr 12
5:20am ET
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Instil Bio (TIL) and Regeneron (REGN)
Apr 11
11:58am ET
RBC sees buying opportunity following Regeneron’s ‘overdone DOJ downside’
Apr 10
4:26pm ET
DOJ files false claims act complaint against Regeneron over drug pricing
Apr 09
6:45am ET
Regeneron (REGN) Receives a Buy from RBC Capital
Apr 09
5:50am ET
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Veeva Systems (VEEV) and Ultragenyx Pharmaceutical (RARE)
Apr 30
9:45pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 25
5:15pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 18
8:00am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 16
10:05pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 15
7:00am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 15
6:00am ET
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 13
6:00am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 12
4:30am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Mar 14
10:40am ET
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
REGN Financials
Key terms
Ad Feedback
REGN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
REGN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
